Compounded Tirzepatide in 2026: Is It Still Available and Is It Safe?
Tirzepatide (the active ingredient in Mounjaro and Zepbound) is the most effective GLP-1 medication available, with weight loss up to 20.9% in clinical trials. But compounded tirzepatide faces even steeper regulatory headwinds than compounded semaglutide — and the availability picture in 2026 is complicated.
Current Regulatory Status
Tirzepatide was removed from the FDA's drug shortage list in 2025. The FDA's current 503B exclusion proposal specifically names tirzepatide alongside semaglutide and liraglutide. For 503A pharmacies, compounding "essentially a copy" of Zepbound or Mounjaro is already prohibited since the shortage ended.
Some 503A pharmacies continue to compound tirzepatide under personalization frameworks — different doses, different formulation bases, combination products — but the legal landscape is more constrained than during the shortage era.
Tirzepatide vs. Semaglutide: Why It Matters
| Factor | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Max weight loss | ~20.9% | ~15% (2.4mg) / ~18.7% (7.2mg pending) |
| Compounded availability | More limited in 2026 | More widely available |
| Compounded pricing | $133–$400/mo | $99–$299/mo |
| Brand pricing | $1,080+/mo (Zepbound) | $1,349+/mo (Wegovy) |
Where to Find Compounded Tirzepatide
Fewer providers offer compounded tirzepatide compared to semaglutide. Those that do typically price it 30–60% higher due to higher API costs.
Brand-Name Alternative
Compare Compounding Pharmacy Providers
See pricing, pharmacy type, and what's included — side by side.
Compare Providers →